Drug Name Target Source Route of administration FDA-approved indication FDA pregnancy category Bioavailability Elimination half-life (days) Volume of distribution Dosage for IBD
Adalimumab[14] TNFα Humana SC IBD, RAd, psoriasis, ankylosing spondylitis B 64% 14 4.7-6 L Day 1: 4 x 40 mg injections in one day or 2 x 40 mg injections per day for two consecutive days Day 15: 80 mg Day 29: a maintenance dose of 40 mg every other week.
Certolizumabpegol [15] TNFα Humanizedb SC IBD B 76-88% 14 6-8 L 400 mg at 0, 2, and 4 weeks. If response occurs, follow with 400 mg every four weeks
Golimumab[16] TNFα Humana SC UC, RA, psoriatic arthritis, ankylosing spondylitis B 53% 14 58-126 ml/kg 200 mg at week 0, followed by 100 mg at week 2, then 100 mg every four weeks
Infliximab [17] TNFα Chimericc IV IBD, RA, psoriasis, ankylosing spondylitis B - 7-12 3-6 L 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks
Natalizumab[18] α4-integrin Humanizedb IV CD, multiple sclerosis C - 3-17 ~5 L 300 mg IV infusion over 1hr every 4 weeks
aEntirely human amino acids; bContaining murine CDRs; cComposed of human constant and murine variable regions; d Rheumatoid arthritis  
Table 1: Biologics commonly used for IBD during pregnancy.